Fenwick Represents Tamir Biotechnology in Acquisition of its Assets by Orgenesis

​​Fenwick & West represented Tamir Biotechnology, Inc., a clinical stage anti-viral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions, in the acquisition of its assets by Orgenesis Inc. (NASDAQ: ORGS).

The acquisition, which includes ranpirnase, TamirBio’s broad spectrum anti-viral platform, will be completed for a combination of stock and cash consideration.

Orgenesis plans to combine ranpirnase with its co-developed Bioxome technology for enhanced payload delivery directly to cells. More information can be obtained from the company’s announcement​.

The Fenwick transaction team included corporate partner Ethan Skerry, associates Zachary Portnoy and Ammanuel Gebeyehu, and law clerk Elijah Porter; executive compensation and employee benefits partner Matthew Cantor; technology transactions partner Stefano Quintini and counsel Claire O’Callaghan; and tax partner William Skinner and associate Ora Grinberg.